ライフサイエンスコーパス: platelet aggregation

1 re bleeding phenotype and complex defects in platelet aggregation.

2 le antithrombotic activity via inhibition of platelet aggregation.

3 S13-mediated proteolysis of VWF and promoted platelet aggregation.

4 inity to the GPIIb/IIIa receptor involved in platelet aggregation.

5 ne proteases, contributes to coagulation and platelet aggregation.

6 R4 gene (F2RL3) associated with PAR4-induced platelet aggregation.

7 receptor for, e.g., fibrinogen and mediates platelet aggregation.

8 nule secretion, which is required to augment platelet aggregation.

9 osphate and thromboxane A2 are mandatory for platelet aggregation.

10 IIbbeta3 (GPIIb-IIIa) with fibrinogen during platelet aggregation.

11 uction to complete inhibition of ADP-induced platelet aggregation.

12 nent clinical drug targets for inhibition of platelet aggregation.

13 P), collagen, and rhodocytin (Rhod)-mediated platelet aggregation.

14 rotease-activated receptor 1 (PAR1)-mediated platelet aggregation.

15 lant platelet formation in the regulation of platelet aggregation.

16 ts into the cellular and molecular basis for platelet aggregation.

17 c outlet region, contributing to exacerbated platelet aggregation.

18 usly unrecognized abnormality that may favor platelet aggregation.

19 and has no activity in coagulation tests or platelet aggregation.

20 lial cell damage, permeability increase, and platelet aggregation.

21 imary brain tumors via its ability to induce platelet aggregation.

22 ceptors (GPCRs), and its activation triggers platelet aggregation.

23 and production of adenosine, an inhibitor of platelet aggregation.

24 face and this abnormality is associated with platelet aggregation.

25 blood and the ability of aspirin to inhibit platelet aggregation.

26 , and plasma factors, such as antibodies, on platelet aggregation.

27 but in contrast inhibited ristocetin-induced platelet aggregation.

28 mit vascular smooth muscle proliferation and platelet aggregation.

29 rs of von Willebrand factor, thus regulating platelet aggregation.

30 biological events, including endocytosis and platelet aggregation.

31 strated increased MBL/MASP complex-dependent platelet aggregation.

32 ide-binding motifs, modulating the extent of platelet aggregation.

33 mechanism to prevent excessive VWF-mediated platelet aggregation.

34 ion of thrombi rather than the prevention of platelet aggregation.

35 nflammation, cell adhesion, vessel tone, and platelet aggregation.

36 ibited thrombin-, ADP-, and collagen-induced platelet aggregation.

37 leads to potent and reversible inhibition of platelet aggregation.

38 Inhibition of miR-126 in mice reduced platelet aggregation.

39 elet inhibition was monitored by ADP-induced platelet aggregation.

40 ing its prothrombotic activity and promoting platelet aggregation.

41 vel alphaIIbbeta3 antagonists, which inhibit platelet aggregation.

42 moderately decreased thrombin-induced human platelet aggregation.

43 s an important signaling molecule regulating platelet aggregation.

44 ts of histones and decreases histone-induced platelet aggregation.

45 resulted in defective ITAM receptor-mediated platelet aggregation.

46 sphodiesterase inhibition, strongly impaired platelet aggregation.

47 ation is distinct from purine involvement in platelet aggregation.

48 reduced nitric oxide-mediated inhibition of platelet aggregation.

49 h platelet TLR4 and promotes agonist-induced platelet aggregation.

50 ecretion, and impaired fibrin generation and platelet aggregation.

51 ng, delta-granule content and secretion, and platelet-aggregation; (2) significant decreases of secre

52 on achieved with 80% proportion PT (residual platelet aggregation 80% PT mix/residual platelet aggreg

53 The percentage restoration of residual platelet aggregation achieved with 80% proportion PT (re

54 actin polymerization after GPIb-IX-mediated platelet aggregation, actin polymerization inhibitors di

55 tide exhibiting both FXa inhibition and anti-platelet aggregation activities, with a low bleeding ris

56 identified with both FXa inhibition and anti-platelet aggregation activities.

57 rimary end point of the study, inhibition of platelet aggregation after arachidonic acid 1.5 mmol/L a

58 s of CPT and NPT showed potent inhibition of platelet aggregation after pretreatment with 1 mM GSH, c

59 far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists describ

60 s at all other time points and inhibition of platelet aggregation; an exploratory analysis evaluated

61 ular smooth muscle cell migration assays and platelet aggregation analyses.

62 acks and abolished the enhanced PAR4-induced platelet aggregation and 1,4,5-triphosphate generation a

63 Reduced platelet aggregation and a mild bleeding phenotype have

64 on assays and viscometer-based shear-induced platelet aggregation and activation studies reduced plat

65 platelet adhesion, as shown by shear-induced platelet aggregation and activation studies.

66 PAF is implicated in platelet aggregation and activation through release of v

67 tures of platelets but significantly impairs platelet aggregation and adenosine triphosphate secretio

68 m Aedes aegypti, binds collagen and inhibits platelet aggregation and adhesion.

69 hate (cGMP)-mediated signaling and inhibited platelet aggregation and arrest under flow.

70 Willebrand factor (VWF), thereby inhibiting platelet aggregation and arterial thrombosis.

71 ation of alphaIIbbeta3, a process leading to platelet aggregation and blood coagulation.

72 as associated with higher PAR4-induced human platelet aggregation and Ca2+ flux, and generated greate

73 Platelet aggregation and calcium mobilization induced by

74 hich has pro-inflammatory effects, increases platelet aggregation and clot strength, and reduces fibr

75 es of RNA levels and associations among RNA, platelet aggregation and demographic variables.

76 iological functions, including inflammation, platelet aggregation and endothelial cell apoptosis, and

77 is associated with concomitant inhibition of platelet aggregation and granule secretion.

78 Rac-1-dependent granule release required for platelet aggregation and hemostasis.

79 ood cell (RBC) transfusion increases in vivo platelet aggregation and inflammation in coronary and no

80 (GPIIb/IIIa) is the key receptor involved in platelet aggregation and is a validated target for thera

81 levels in Ip6k1(-/-) mice, along with slower platelet aggregation and lengthened plasma clotting time

82 hear rates (3000-10 000 seconds(-1)) induced platelet aggregation and metalloproteinase-dependent app

83 efractory to granulocyte CSF, from defective platelet aggregation and myelofibrosis.

84 al insight into the underlying mechanisms of platelet aggregation and platelet activation heterogenei

85 ding order of potency for effects on maximal platelet aggregation and platelet response units.

86 fold increase in inhibitory activity against platelet aggregation and release reactions in response t

87 Thrombin- or collagen-induced platelet aggregation and secretion are increased in TRAF

88 We found that platelet aggregation and secretion in response to 2-meth

89 In contrast, 2-MeSADP- and AYPGKF-induced platelet aggregation and secretion were minimally affect

90 ent hydrolase of Ap3A capable of stimulating platelet aggregation and secretion.

91 rs are expressed on platelets, which mediate platelet aggregation and shape change.

92 nding to the integrin alphaIIbbeta3 mediates platelet aggregation and spreading on fibrinogen-coated

93 Interestingly, unlike CRP, platelet aggregation and Syk phosphorylation induced by

94 We conclude that ATL regulates neutrophil-platelet aggregation and that platelet-neutrophil intera

95 dent negative feedback mechanism that limits platelet aggregation and thrombotic occlusion.

96 in fluid mechanical conditions that promote platelet aggregation and thrombus formation by increased

97 versibly block substrate binding and inhibit platelet aggregation and thrombus formation in vivo.

98 of G-protein-coupled receptors in supporting platelet aggregation and thrombus formation.

99 platelet reactivity, and in so doing blunts platelet aggregation and thrombus formation.

100 hemostatic potential is important to mediate platelet aggregation and to recruit platelets to the sub

101 gger CD36-dependent JNK2 activation, enhance platelet aggregation, and accelerate thrombus formation.

102 adhesion to surface-coated PEAR1, diminished platelet aggregation, and eliminated PEAR1 phosphorylati

103 thrombocytosis, exaggerated agonist-induced platelet aggregation, and enhanced extra-intestinal thro

104 ted with production of procoagulant factors, platelet aggregation, and facilitation of thrombotic eve

105 of intravascular thrombin activity, reduced platelet aggregation, and improved microvascular perfusi

106 mage, inflammation, vascular reactivity, and platelet aggregation, and improvement in immune function

107 cular physiology, specifically vasodilation, platelet aggregation, and leukocyte rolling.

108 iological functions, including vasodilation, platelet aggregation, and neurotransmission.

109 rotein coupled, 12) plays a critical role in platelet aggregation, and P2RY12 inhibitors are used cli

110 , A23187-induced thromboxane A(2) synthesis, platelet aggregation, and secretion were inhibited by pr

111 hysiological processes such as vasodilation, platelet aggregation, and synaptic plasticity.

112 all shown to inhibit alphaIIbbeta3 dependent platelet aggregation, and these inhibitors became the fo

113 phate, the P2Y1 receptor (P2Y1R) facilitates platelet aggregation, and thus serves as an important an

114 te thrombocytopenia; absent collagen-induced platelet aggregation; and large, fused alpha-granules in

115 ses such as cell adhesion, vasoconstriction, platelet aggregation, angiogenesis, inflammatory gene ex

116 rs6566765 associations with agonist-induced platelet aggregation are novel.

117 nd convulxin (CVX) (IC50 = 5.7 muM) mediated platelet aggregation as compared to losartan (LOS) (coll

118 th nanomolar potency in the disease-relevant platelet aggregation assay in human plasma.

119 atelet activity was evaluated using the anti-platelet aggregation assay.

120 Platelet aggregation assays with citrated platelet-rich

121 nhibition was borne out in whole human blood platelet aggregation assays.

122 rmore, we show that NPP1 is unable to induce platelet aggregation at physiologic concentrations repor

123 Platelet aggregation at sites of vascular injury is esse

124 Platelet aggregation at sites of vascular injury is not

125 Platelet aggregation at the site of vascular injury is e

126 emostasis in vivo by augmenting ADP-mediated platelet aggregation at the site of vascular injury.

127 may represent a novel mode of regulation of platelet aggregation at the vascular wall.

128 ) were expressed and discovered to attenuate platelet aggregation, ATP secretion, and thromboxane A2

129 otype associated with increased clotting and platelet aggregation attributable to a promoter variant

130 otent P2Y(1)(2) antagonists as inhibitors of platelet aggregation based on a phenylpyrazole glutamic

131 ual platelet aggregation 80% PT mix/residual platelet aggregation baselinex100) significantly decreas

132 METHODS AND RESULTS- We measured ex vivo platelet aggregation before and after dual antiplatelet

133 racellular signaling inhibited shear-induced platelet aggregation but minimally affected shear-induce

134 Gi signaling; this is insufficient to cause platelet aggregation, but it is enough to predispose pla

135 phil oxidative burst and negatively modulate platelet aggregation by a unique salivary mechanism.

136 osphotyrosine-binding (PTB) domain, inhibits platelet aggregation by competing with fibrinogen for al

137 Thrombin initiates human platelet aggregation by coordinately activating proteina

138 Among these, active MMP-2 enhances platelet aggregation by favoring the activation of phosp

139 ayed generation of fIIa(MZ) enzyme activity, platelet aggregation by fII(MZ) is similar to fII(WT) Co

140 These data suggest that MRP4 promotes platelet aggregation by modulating the cAMP-protein kina

141 tream of CD36 that are critical in promoting platelet aggregation by oxLDL.

142 displayed enhanced inhibition of ADP-induced platelet aggregation by the nitric oxide donor sodium ni

143 The attenuation of platelet aggregation by the phosphodiesterase inhibitor

144 During platelet aggregation by various agonists, the membrane e

145 ochemical endpoints were measured, including platelet aggregation, calcium mobilization, and integrin

146 t S. aureus lipoteichoic acid (LTA) inhibits platelet aggregation caused by physiological agonists an

147 Key to platelet aggregation, CD41 expression also characterises

148 n expression in primary brain tumors induces platelet aggregation, correlates with hypercoagulability

149 s reports have shown that rhodocytin-induced platelet aggregation depends on secondary mediators such

150 ver, flavocetin-A inhibited collagen-induced platelet aggregation even after GPIb was blocked with ot

151 The absence of Jam-A results in increase in platelet aggregation ex vivo.

152 PGN induced platelet aggregation, expression of the activated form o

153 wed a significant reduction in PAR4-mediated platelet aggregation, fibrinogen binding, and P-selectin

154 an platelets or its deletion in mice reduces platelet aggregation, fibrinogen binding, granule secret

155 Cx37 gene (Gja4) in transgenic mice reduced platelet aggregation, fibrinogen binding, granule secret

156 ine (0.1-100 microM) significantly increased platelet aggregation harvested from healthy volunteers i

157 We have previously shown that platelet aggregation has higher heritability in African

158 multimers (ULVWF), which are prone to induce platelet aggregation; however, the actual trigger of TTP

159 did not suffer from bleeding and have normal platelet aggregation; however, their platelets mimicked

160 tiple mosquito salivary components mediating platelet aggregation (i.e., Aegyptin, apyrase, D7) repre

161 aIIbbeta3 and ability to inhibit ADP-induced platelet aggregation (IC50) showed that two designed lig

162 orted in human blood, but it could stimulate platelet aggregation if localized at low nanomolar conce

163 r, a genome-wide association study (GWAS) of platelet aggregation in African Americans has not been r

164 In this first GWAS of agonist-induced platelet aggregation in African Americans, we discovered

165 A mathematical model of platelet aggregation in heterogeneous mixtures was devel

166 ylurea chemotype that inhibited ADP-mediated platelet aggregation in human blood samples is described

167 vated thrombin induces fibrin deposition and platelet aggregation in microvessels.

168 (Impact of Prasugrel Re-load on Platelet Aggregation in Patients on Chronic Prasugrel Th

169 We measured platelet aggregation in response to arachidonic acid, AD

170 occurrence of bleeding events and decreased platelet aggregation in response to collagen in platelet

171 y effect on resting platelets, cLDL enhanced platelet aggregation in response to different agonists.

172 Platelet aggregation in response to primary human gliobl

173 ular integrity; this function is mediated by platelet aggregation in response to recognition of the e

174 as an important function preventing maternal platelet aggregation in response to the early developing

175 nhibition of 12-LOX significantly attenuates platelet aggregation in response to various agonists.

176 iminished neutrophil adhesion and neutrophil-platelet aggregation in SCD mice, thereby improving bloo

177 GPVI-Fc reduced plaque-triggered platelet aggregation in static blood by 51%, BLO8-1 by 8

178 The relative inhibition of platelet aggregation in the chewing vs the standard grou

179 eptor but also a low nanomolar inhibition of platelet aggregation in the human platelet rich plasma a

180 ulting in spatially confined and exacerbated platelet aggregation in the stenosis outlet region.

181 itions in a stenotic artery, showed enhanced platelet aggregation in the stenotic outlet region at 60

182 e target organ with rapid onset of extensive platelet aggregation in the ventricles and myocardial ne

183 vel promising tool, which allows analysis of platelet aggregation in thrombocytopenic patients or inf

184 wed by the luminal release of VWF fibers and platelet aggregation in tumor microvessels.

185 is enhanced, with a concomitant increase in platelet aggregation in vitro and a reduced duration of

186 were able to inhibit both thrombin-triggered platelet aggregation in vitro and clot consolidation in

187 Furthermore, 3A inhibits platelet aggregation in vitro and elongates bleeding tim

188 nzymatic basis for NPP4 and Ap3A activity in platelet aggregation in vitro and suggest that NPP4 prom

189 and selective COX-1 inhibitors that affected platelet aggregation in vitro through the inhibition of

190 uman HIT IgG-induced platelet activation and platelet aggregation in vitro, and thrombus progression

191 h plasma from Fib(AEK) mice supported normal platelet aggregation in vitro, highlighting that fibrino

192 osquitoes failed to inhibit collagen-induced platelet aggregation in vitro.

193 coronary arteries and reciprocally regulated platelet aggregation in washed human platelets.

194 onitor fibrin formation and fibrinolysis and platelet aggregation in whole blood.

195 cy of the drug eptifibatide, which decreases platelet aggregation, in the context of HUS.

196 ave developed a novel flow cytometry test of platelet aggregation, in which 10- to 25-fold lower plat

197 xamination of mice lacking integrin-mediated platelet aggregation indicated that platelet aggregation

198 al cells (ECs) showed enhanced inhibition of platelet aggregation induced by adenosine 5'-diphosphate

199 el with a Ki value of 9.02 muM and inhibited platelet aggregation induced by ADP and U46619 in a dose

200 in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferati

201 times as well as reduced thrombus formation, platelet aggregation, inflammation, and organ damage dur

202 ing dose is feasible, and it does not hinder platelet aggregation inhibition in patients with acute c

203 ding further support for the hypothesis that platelet aggregation inhibition is a vital salivary func

204 Aegyptin did not affect salivary ADP-induced platelet aggregation inhibition or disturb anticlotting

205 ) and 3 antithrombotic/anticoagulant agents (platelet aggregation inhibitors excluding heparin, direc

206 This also can be useful for the design of platelet-aggregation-inspired engineering solutions.

207 Platelet aggregation, integrin alphaIIbbeta3 activation,

208 ogrel therapy, device-reported inhibition of platelet aggregation (IPA) trended lower in nonsmokers t

209 Indeed, excessive platelet aggregation is associated with myocardial infar

210 s whereas Glanzmann thrombasthenia, in which platelet aggregation is reduced, is a bleeding syndrome.

211 In particular, platelet aggregation is routinely measured in an aggrego

212 Adenosine diphosphate (ADP)-mediated platelet aggregation is signaled through two distinct G

213 Genetic attenuation of maternal platelet aggregation is similarly ineffective.

214 atelets and released upon tumor cell-induced platelet aggregation, leading to the production of LPA.

215 tion on hematopoietic cells is essential for platelet aggregation, leukocyte adhesion, and transmigra

216 Further, we couple the calibrated platelet aggregation model with a tissue-factor/contact

217 ary comparison was noninferiority of maximum platelet aggregation (MPA) comparing the median for pras

218 12) platelet reactivity index (PRI), maximal platelet aggregation (MPA) to adenosine phosphate, and V

219 weight (HBW) patients as assessed by maximal platelet aggregation (MPA).

220 xtracellular space during the second wave of platelet aggregation on activation.

221 Morphine delayed the maximal inhibition of platelet aggregation on average by 2 h (n = 24; p < 0.00

222 ailable antithrombotic agents inhibit either platelet aggregation or fibrin generation, inhibition of

223 duce a productive functional response, be it platelet aggregation or leukocyte extravasation.

224 Six SNPs were significantly associated with platelet aggregation (P<5x10(-8)) in the discovery sampl

225 egometry (11.6% relative increase in maximal platelet aggregation, p = 0.004; 10.8% increase in resid

226 ation, p = 0.004; 10.8% increase in residual platelet aggregation, p = 0.005) and vasodilator-stimula

227 ggregation, p = 0.04, and 12.7% for residual platelet aggregation, p = 0.02) but not with collagen or

228 ide (relative increases of 11.7% for maximal platelet aggregation, p = 0.04, and 12.7% for residual p

229 pathways, the anticoagulant pathway and the platelet aggregation pathway.

230 One mystery in the mechanism of platelet aggregation pertains to how resting platelets i

231 The fact that nitroxyl (HNO) reduces platelet aggregation, preconditions against myocardial i

232 blood pressure regulation and inhibition of platelet aggregation require sGC activation by NO.

233 DSS treatment also enhanced the platelet aggregation response to thrombin and accelerate

234 telets, platelet life span, thrombin-induced platelet aggregation response, and light/dye-induced thr

235 and demonstrated higher collagen-stimulated platelet aggregation responses (p = 0.04) than men.

236 At rest, women had heightened platelet aggregation responses to serotonin (p = 0.007)

237 Although platelet aggregation responses were not affected, a defe

238 sly in 3 pedigrees with bleeding and reduced platelet aggregation responses.

239 at elevated levels of plasma 5-HT accelerate platelet aggregation resulting in a hypercoagulable stat

240 We found that platelet aggregation, secretion, and spreading were dimi

241 e inside-out pathway as an approach to block platelet aggregation should be paralog-specific, as it m

242 ing array of biological functions, including platelet aggregation, smooth muscle cell proliferation,

243 58), was associated with reduced ADP-induced platelet aggregation (Spearman's rank correlation coeffi

244 mediated platelet aggregation indicated that platelet aggregation stabilizes thrombi that form in the

245 virulent infection, including signatures for platelet aggregation, stronger and prolonged anemia and

246 ssments, transthoracic echocardiography, and platelet aggregation studies at baseline and after 3 men

247 Moreover, platelet aggregation studies showed a higher response to

248 platelet integrin mechanics and its role in platelet aggregation, suggesting that platelets are phys

249 duce TXA2 generation, but rather accelerated platelet aggregation, suggesting that the role of LIMK1

250 ition, 23 potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhi

251 latelet adhesion and clot retraction but not platelet aggregation, supporting the role of these regio

252 tients does not exhibit a full inhibition of platelet aggregation, termed 'aspirin resistance' (AR).

253 When platelet aggregation tests (PATs) were performed with pl

254 iovascular system from drugs used to inhibit platelet aggregation, the focus of this article will be

255 letion in mice resulted in modestly enhanced platelet aggregation, the formation of large thrombi and

256 C-type lectin-like receptor 2-induced human platelet aggregation, thereby phenocopying the effect of

257 for pathological conditions associated with platelet aggregation/thrombi (e.g., stroke), where vWF l

258 mouse models of sepsis, we observed profound platelet aggregation, thrombin activation, and fibrin cl

259 This interaction results in maternal platelet aggregation, thrombosis of the maternal blood,

260 sis, denudation of the underlying matrix and platelet aggregation, thrombotic microangiopathy, and ne

261 Assays measuring platelet aggregation (thrombus formation) at arterial sh

262 raise intra-platelet cAMP levels and inhibit platelet aggregation through a P2Y(12)-independent mecha

263 agonist that induces integrin activation and platelet aggregation through its receptors P2Y(1) (Galph

264 n P2Y(12) platelet reactivity index, maximal platelet aggregation to 5 and 20 mumol/l adenosine dipho

265 platelet RNA and expression-1 study measured platelet aggregation to arachidonic acid, ADP, protease-

266 Dense granules are important in platelet aggregation to form a hemostatic plug as eviden

267 L5 enhanced adenosine diphosphate-stimulated platelet aggregation twofold more than did L1 and induce

268 ciated AKT2 regulates heterotypic neutrophil-platelet aggregation under shear conditions.

269 odies inhibit atherosclerotic plaque-induced platelet aggregation under static and flow conditions mo

270 ns bear the GPVI-binding sites that initiate platelet aggregation upon blood exposure during injuries

271 protein expression by Western blot analysis, platelet aggregation using an aggregometer, and shear st

272 patients with measured on-aspirin treatment platelet aggregation values directly before PCI.

273 Platelet aggregation values were similar across ABCB1 C3

274 onize their hosts' hemostasis, which include platelet aggregation, vasoconstriction and blood clottin

275 eptor blockade we confirm that NPP4 mediates platelet aggregation via release of ADP from Ap3A and ac

276 gregation receptor-1 (PEAR1) participates in platelet aggregation via sustaining alphaIIbbeta3 activa

277 otein on brain vascular endothelium inducing platelet aggregation via the hydrolysis of Ap3A, whereas

278 Defective platelet aggregation was accompanied by impaired inside-

279 genotyped for ABCB1 C3435T, and ADP-induced platelet aggregation was assessed in whole blood on a Mu

280 Whole blood platelet aggregation was enhanced, and plasma fibrinogen

281 Platelet aggregation was explored through a spectrophoto

282 Residual platelet aggregation was higher 1 to 4 h after morphine

283 Platelet aggregation was measured by impedance aggregome

284 Human atherosclerotic plaque-induced platelet aggregation was measured in anticoagulated bloo

285 Platelet aggregation was measured using multiple electro

286 Platelet aggregation was measured using P2Y12 reaction u

287 No relevant difference in platelet aggregation was observed between the 2 study ar

288 Residual platelet aggregation was significantly reduced in both a

289 s creatine kinase level of 4664, ADP-induced platelet aggregation was undetectable, normalizing after

290 sfusion measurements of maximal and residual platelet aggregation were considered with different agon

291 brinogen binding, P-selectin expression, and platelet aggregation were lower on treatment with clopid

292 Endothelial activation and platelet aggregation were normal in PAD4(-/-) mice, as w

293 adenosine diphosphate-, or thrombin-induced platelet aggregation were significantly attenuated in Ty

294 Interestingly, pFn promoted platelet aggregation when linked with fibrin but inhibit

295 rterio-venous shunt model was used to assess platelet aggregation, whereas a healthy rabbit model of

296 tococci in biofilms were also able to induce platelet aggregation, which facilitates multilayer biofi

297 This is distinct from platelet aggregation, which is critical for the maintena

298 , BLO8-1 and 5C4 almost completely inhibited platelet aggregation while preserving platelet adhesion

299 in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of

300 ability and faster and greater inhibition of platelet aggregation with arachidonic acid compared with